What does the Novo Nordisk partnership mean for Hims?

Hims will be able to offer branded GLP-1 obesity drugs, including Wegovy, on its platform. This reduces legal risk and opens a fast-growing therapy category. The upside depends on supply consistency, pricing, and prescription conversion. Expect more clarity once the rollout begins and early patient onboarding data appears.

Is hims stock attractive for Canadian investors right now?

It is interesting after the partnership news, but risk remains. Valuation is mid-range on sales, margins are improving, and growth is strong. Technicals show near-oversold readings. Consider staged entries, watch supply updates, and reassess after the May 4 earnings report for guidance and GLP-1 traction.

When could Wegovy be available on the Hims platform?

Reporting indicates as soon as Monday. Actual access will still require a valid prescription, clinical eligibility, and payment or coverage. Availability can vary by location and plan. Investors should watch for company updates on timing, fulfillment rates, and patient continuity of care during the first weeks.

What are the main risks to the hims stock thesis?

Key risks include limited drug supply, high acquisition costs, weaker-than-expected conversion, and pricing or reimbursement pressure. There is also execution risk integrating GLP-1 programs. Leverage is not low, so cash flow timing matters. A miss on margins or guidance could weigh on sentiment.

Global Market Insights

HIMS Stock Today: March 07 — Novo Truce Brings Obesity Drugs to Platform

ByDanny Kontos March 8, 2026March 8, 2026

Hims stock is back in focus for Canadian investors after Hims & Hers and Novo Nordisk reached a truce that will bring branded weight loss drugs like Wegovy to the Hims platform as soon as Monday, according to Bloomberg. This Novo Nordisk partnership removes legal risk and opens the fast growing GLP-1 obesity drugs category to Hims users. We explain why HIMS could benefit, what today’s price and valuation say, and how to plan entries ahead of the next earnings update.